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Abstract: Inflammation promotes endothelial dysfunction, but the underlying mechanisms remain
poorly defined in vivo. Using translational vascular function testing in myocardial infarction patients,
a situation where inflammation is prevalent, and knock-out (KO) mouse models we demonstrate a
role for mitogen-activated-protein-kinases (MAPKs) in endothelial dysfunction. Myocardial infarc-
tion significantly lowers mitogen and stress kinase 1/2 (MSK1/2) expression in peripheral blood
mononuclear cells and diminished endothelial function. To further understand the role of MSK1/2
in vascular function we developed in vivo animal models to assess vascular responses to vasoac-
tive drugs using laser Doppler imaging. Genetic deficiency of MSK1/2 in mice increased plasma
levels of pro-inflammatory cytokines and promoted endothelial dysfunction, through attenuated
production of nitric oxide (NO), which were further exacerbated by cholesterol feeding. MSK1/2
are activated by toll-like receptors through MyD88. MyD88 KO mice showed preserved endothelial
function and reduced plasma cytokine expression, despite significant hypercholesterolemia. MSK1/2
kinases interact with MAPK-activated proteins 2/3 (MAPKAP2/3), which limit cytokine synthesis.
Cholesterol-fed MAPKAP2/3 KO mice showed reduced plasma cytokine expression and preservation
of endothelial function. MSK1/2 plays a significant role in the development of endothelial dysfunc-
tion and may provide a novel target for intervention to reduce vascular inflammation. Activation of
MSK1/2 could reduce pro-inflammatory responses and preserve endothelial vasodilator function
before development of significant vascular disease.
Keywords: endothelium; vascular biology; vascular disease; MAPK; cytokine
1. Introduction
Inflammation is a major driver in the development of atherosclerosis [1–3]. It pro-
motes early endothelial dysfunction [4] as well as playing an important role in ischemia
reperfusion following acute myocardial infarction (AMI). Blood cytokines are predictive of
future adverse cardiovascular events [5–7] and local inflammation in tissues is associated
with tissue injury and immune cell recruitment.
Cytokine release can be induced through numerous pathways. Importantly, toll-like
receptors (TLRs) induce the expression of pro-inflammatory genes that are associated with
atherosclerosis [8]. TLRs are also upregulated on peripheral blood monocytes following
AMI [9] and on activated endothelial cells [10,11]. The regulation of cytokine expression
downstream of TLRs is complex and involves recruitment of myeloid differentiation
primary response-88 (MyD88), initiating downstream signals through multiple signalling
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pathways, including p38α mitogen-activated protein kinase (MAPK). Inhibition of p38 in
a model of atherosclerosis reduces plaque formation [12] and preserves cardiac function
in a model of heart failure [13]. However, clinical trials of p38 inhibition have shown no
therapeutic effect on cardiovascular disease (CVD) outcome [14].
While p38α has inflammatory roles, recent work shows it can also have anti-inflammatory
functions [15]. For example, mice with a myeloid specific deletion in p38α show increased
pathology in an ultraviolet-B induced skin inflammation model [16]. The effects of p38 in
inflammation are in part mediated by two groups of down-stream kinases, mitogen and
stress kinase (MSK) 1 and 2 and MAPK-activated protein kinases (MAPKAPK) 2 and 3.
MSK1 and 2 have been found to be important in mediating the anti-inflammatory functions
of p38α [16,17].
MSK1 and 2 are nuclear kinases that are activated downstream of p38α MAPK and
serve to help regulate the induction of immediate early genes [18]. TLR signalling in
macrophages has been shown to activate MSKs and this promotes transcription of sev-
eral genes with anti-inflammatory functions including interleukin-10 (IL-10) and IL-1
receptor antagonist (IL-1ra) [16,17,19]. MSKs also regulate the induction of a dual speci-
ficity phosphatase (DUSP1) [16], which is involved in deactivation of p38α and c-Jun
N-Terminal kinases (JNK) downstream of TLR signalling [20]. Consequently, MSK1/2
double knockout (KO) mice show increased sensitivity to liposaccharide (LPS) induced
endotoxic shock, which is accompanied by increased induction of tumour necrosis factor
(TNF), interleukin-6 (IL-6) and IL-12 relative to wild-type (WT) animals [16]. In contrast to
MSKs, MAPKAPK2/3 are important in mediating the pro-inflammatory effects of p38α.
MAPKAPK2 deficient animals display significant attenuation of TNF-α production in
response to LPS [21], resistance to the development of rheumatoid arthritis (RA) [22],
and a reduction in atherosclerotic lesion formation [23]. However, the role of these ki-
nases in the development of early vascular inflammation and endothelial dysfunction
remains unknown.
The aim of the present study was to examine the role of MSKs in CVD. AMI is as-
sociated with substantial impairment of endothelial function and inflammation in both
the infarcted myocardium and myocardium perfused by normal vessels [24,25]. The deter-
minants of endothelial dysfunction that contribute to the extent of ischemia and necrosis
after AMI are not fully elucidated. It is not known if MSK1/2 are involved in endothelial
dysfunction following AMI. In this study, we examined patients presenting with AMI,
and obtained peripheral blood mononuclear cells (PBMCs) for evaluation of MSK1/2
expression and to determine the association of this expression with endothelial function
in vivo. We hypothesized that there is a link between expression of MSK1/2 and endothe-
lial dysfunction. To examine this relationship in more detail, we used an in vivo MSK1/2
KO mouse model to longitudinally assess the functional role of MSK1/2 in development
of endothelial dysfunction, a known precursor for CVD development. Additionally, we
used MyD88 and MAPKAPK2/3 deficient mouse models to examine proteins upstream
and downstream of p38α to better understand the role of innate immune signalling in the
development of endothelial dysfunction in vivo.
2. Materials and Methods
2.1. Human Cohort of ST-Elevation Myocardial Infarction (STEMI) Patients
We recruited 35 patients who were admitted to hospital with STEMI and under-
went percutaneous coronary intervention (PCI) at Ninewells Hospital Coronary Care Unit.
Patients provided written, informed consent for the collection of bloods for the isolation
of PBMCs and for endothelial function testing within 12–100 h post-PCI investigation
conformed to the principles outlined in the Declaration of Helsinki and local ethical
approval was granted by review boards at the University of Dundee. A further 28 age-
matched healthy volunteers were recruited as controls (Supplemental Table S1). Exclusion
criteria were <18 years of age, unable to give written consent and undergoing current
cancer treatments. Additional exclusion criteria for healthy volunteers, included medical
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history of vascular diseases such as peripheral arterial disease, stroke, hypertension, and
haematological conditions such as hypercoagulability and deep venous thrombosis. A
sample size of 40 subjects in each group was projected to provide >90% power at a 5%
level of significance to detect a 15% difference in gene expression between groups post-PCI
and at least 90% power and 5% significance to detect a 2% difference in flow-mediated
dilatation (FMD).
2.2. Assessment of Endothelial Function in Humans—Flow Mediated Dilatation
Endothelial function was assessed by measuring FMD of the brachial artery using
an 8–15 MHz linear array ultrasound probe (Sequoia 512, Siemens, Camberley, UK) as
described previously [26–28]. We assessed the endothelium-independent response by
following administration of 0.4 mg sublingual glyceryl trinitrate (GTN). Additionally,
for assessing microvascular function, we obtained blood flow velocity measurements
using Doppler ultrasound at baseline and after 5 min of upper arm arterial occlusion as
described previously [29].
2.3. Isolation of Peripheral Blood Mononuclear Cells (PBMCs) RNA
PBMCs were isolated from whole blood using density gradient centrifugation over
Ficoll-Paque (GE-Health Care Life Sciences, Illinois, United States). PBMCs were stored in
fetal bovine serum (FBS) and dimethyl sulphide (DMSO) (10%) at −80 ◦C.
2.4. RT-qPCR
2.4.1. RNA Isolation and cDNA Synthesis
Isolation of RNA from PBMCs was performed using the guanidium-thiocyanate
phenol-chloroform TRIzol (ThermoFisher, Waltham, United States) method. Briefly, frozen
samples of PBMCs were thawed before centrifugation at 1000 rpm for 5 min at 4 ◦C.
Freezing medium was carefully removed from the pelleted PBMCs and the cells were
resuspended in cold PBS and centrifuged at 1000 rpm for 5 min at 4 ◦C. This step was
repeated once more before removing the final PBS wash and adding 1 mL of TRIzol solution.
Cells were lysed by pipetting and left at room temperature for 5 min. Then, 200 µL of
chloroform was added to the TriZol-cell mixture and vigorously mixed. Samples were
then rested at room temperature for 4 min before a centrifugation at 13,000 rpm for 15 min
at 4 ◦C. Centrifugation of this mix produces phase separation of the sample, from which
the upper aqueous phase containing the RNA was removed and transferred to fresh tube.
To the collected aqueous phase, 500 µL isopropanol was added before a brief mix using
a vortexer. The mixture was then left to stand at room temperature for 10 min to allow
the RNA to precipitate. The RNA was then pelleted by centrifugation at 13,000 rpm for
10 min at 4 ◦C. The isopropanol supernatant was then removed and replaced by 1 mL of
a 75% ethanol wash and vortexed. A subsequent centrifugation at 10,600 rpm for 5 min
at 4 ◦C permitted the collection of an RNA pellet. The ethanol wash was removed and
the samples were briefly dried by evaporation in a fume hood before resuspension in
20 µL DEPC-treated deionised water. RNA concentrations were then determined using
a Nanodrop-8000 Spectrophotometer (ThermoFisher, Waltham, MA, USA) according to
manufacturer guidance. RNA was deemed acceptance for cDNA synthesis when the ratio
of absorbance at 260:280nm was 2.0 or greater.
2.4.2. cDNA Synthesis
cDNA was reversed transcribed using the Superscript II (First strand) cDNA synthesis
kit (ThermoFischer) according to the supplier’s instructions. Briefly, RNA samples were
diluted using DEPC-deionised water to 100 ng per sample before the addition of a master
mix containing 1 µL random primers and 1 µL deoxynucleoside triphosphate (dNTPs)
per sample. Samples were then heated to 65 ◦C for 5 min before being transferred to wet
ice. A second mastermix containing 4 µL 5× First-Strand buffer (FSB) (ThermoFischer)
and 2 µL Dithiothreitol (DTT) (ThermoFisher, Waltham, United States) was added per
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sample before a 2 min incubation at room temperature. Superscript II Reverse Transcriptase.
(ThermoFischer) (1 µL) was then added to the mixture before incubation at 42 ◦C for 50 min.
A final incubation at 72 ◦C for 15 min terminated the reaction.
2.4.3. TaqMan RT-PCR
Real-Time PCR was performed using TaqMan gene expression assay probes from Ther-
moFisher (Waltham, United States) (Hs01046591_m1 (MSK1), Hs01071879_m1 (MSK2) and
Hs01060665_g1 (ACTB) and TaqMan 2× Universal PCR Mastermix (Applied Biosystems)
on a QuantStudio™ 7 Flex qPCR machine. (ThermoFischer Scientific Inc., Waltham, United
States). cDNA samples were diluted with DEPC-treated deionised water to a concentration
of 12.5 ng. PCR conditions were as follows; 10 min hold at 95 ◦C for DNA denaturation
followed by 40 cycles, where samples are reheated to 95 ◦C for 15 s and cooled to 60 ◦C
for 1 min. Cycle thresholds (CT) was obtained from the qRT-PCR machine for each gene
target. The average CT values were obtained from the ∆∆CT method, using ACTB as a
‘housekeeping’ gene. Fold change was determined using the 2-(∆∆Ct) method.
2.5. Mouse Models
All experiments were performed under UK Home Office Licences and conducted
according to the Animals Scientific Procedures Act 1986 (UK) and directive 2010/63/EU
of the European Parliament guidelines on the protection of animals used for scientific
purposes. All experiments were approved by the Institutional Animal Welfare and Ethical
Review Body. All animals were euthanized in accordance with local, national UK, and
EU guidelines.
All mice were male and aged-matched to the WT controls. WT and MSK1/2 double
KO [30], MyD88 KO [31] and MAPKAP 2/3 double KO mice [21] were obtained from
breeding facilities at the University of Dundee. All mice were backcrossed onto C57Bl6/J
(Charles River Laboratories, Bristol, UK) mice for a minimum of 12 generations.
2.6. Animal Husbandry and Group Allocation
Adult (10–16 weeks of age) mice were housed in groups of up to six. Diets consisted
of standard rodent chow (Special Diets Services (SDS), Essex, UK): Mice were fed diet
numbers 1 or 3 and sterilized distilled water fed ad libitum, unless otherwise stated.
Animals were transferred from a barrier breeding facility to the experimental facility (in
which the necessary equipment was installed) at least one week before vascular function
testing, to allow acclimation and to avoid stress. Animals were randomly allocated into
four groups: WT control mice were fed a normal rodent chow, WT mice on a cholesterol
diet (TD.01383 diet, Harlan-Teklad; 18% protein rodent chow with added cholesterol
2% by weight), and KO mice on normal rodent chow and a cholesterol diet as detailed
above. Researchers were blinded to genotypes in the group allocations during vascular
assessments for the study duration.
2.7. Assessment of Endothelium-Dependent Responses
Skin microvascular responses were measured longitudinally in the same animals at
4-week intervals following baseline measurements using laser Doppler imaging (LDI) as
described previously [32,33]. Animals were anaesthetized using 5% Isoflurane (Abbot
Laboratories, Chicago, United States) in oxygen (2 L/min), which was delivered using a
standard Boyle’s Apparatus and maintained by delivering 1.5–2% Isoflurane via a nose cone
for the duration of the procedure. Iontophoresis chambers were initially filled with ~2 mL
of 1% solution of the α1-adrenergic receptor agonist phenylephrine (PE) (Sigma-Aldrich,
St. Louis, United States). Following constriction, PE was washed out of the chamber with
deionized water and replaced with a 2% solution of the endothelium-dependent vasodilator
acetylcholine (ACh) (Sigma-Aldrich, St. Louis, United States). ACh was iontophoresed
for 10 min using an anodal current of 100 µA and the maximum vasodilator response
measured by LDI.
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2.8. Role of Nitric Oxide in Endothelium-Dependent Responses
At baseline, assessment of microvascular responses to ACh were repeated in a separate
group of WT and MSK1/2 KO mice (n = 8 in each group) following pre-treatment with the
non-selective inhibitor of nitric oxide synthase (NOS), N (G)-nitro-L-arginine methyl ester
hydrochloride (L-NAME, Sigma-Aldrich, St. Louis, United States). These experiments
explored the importance of NO in endothelium-dependent dilatation in our model of
inflammation. L-NAME was administered by intraperitoneal injections (i.p.) (20 mg/kg in
deionized water).
2.9. Assessment of Endothelium-Independent Responses
Following pre-constriction with PE, a 2% solution of sodium nitroprusside (SNP)
(Sigma-Aldrich) was iontophoresed on the opposite flank of the animal using a 100 µA
cathodal current for 10 min to test endothelium-independent vasodilation. To reduce the
amount of time that each animal was under general anaesthetic and to limit the amount of
drug exposure, responses to SNP were only measured at the end point of the study.
2.10. Maximum Vasodilator Response to Localised Skin Heating
A skin heating probe (SH02™ Skin Heating Unit and SHP3 probe, Moor Instru-
ments, Axminster, UK) with a total surface area of 3.2 cm2 was attached to the flank using
double sided adhesive rings. Baseline measurements of skin perfusion were taken for
5 min, followed by localized heating of the skin at a rate of 1 ◦C/min until a maximum
temperature of 44 ◦C was achieved. This was maintained for 10 min and the maximum
vasodilator response was measured.
2.11. Blood Sampling
Blood was collected by tail bleeds at baseline and by cardiac puncture at study end
point into heparinized microtubes (BD Microtainer TM Lithium Heparin, Franklin Lakes,
NJ, USA) to produce plasma by centrifugation. Plasma was stored at −80 ◦C until analysed.
2.12. Plasma Cholesterol
Total cholesterol was measured using a colorimetric assay (Biovision Inc, catalog#:
K603–100, Milpitas, United States) high-density lipoprotein (HDL) and low-density/very
low-density lipoproteins (LDL/vLDL) fractions were quantified by using a color metric
assay (Abcam, Product code: ab655390) as detailed in the manufacturer’s instructions.
2.13. Cytokine Analysis
Plasma was analyzed using Bio-Plex® Precision ProkitsTM from BIO-RAD laboratories,
Hercules, United States, for IL-1α, IL-6, IL-10, TNF-α, E-selectin as detailed in the manufac-
turer’s instructions. This technique utilizes magnetic beads for multiplex quantification of
cytokines in a single sample.
Cell Culture
C57BL/6 mouse primary dermal microvascular endothelial cells (Cell Biologics,
Chicago, IL, USA) were seeded into tissue culture plates at equal densities in complete
mouse endothelial cell medium with the supplement kit (Cell Biologics, Chicago, IL, USA).
Cells were stimulated as indicated with 100 ng/mL LPS, 400 ng/mL phorbol 12-myristate-
13-acetate (PMA), 10µg/mL anisomycin (aniso), recombinant mouse IL-1α (5 ng/mL) and
recombinant mouse TNF-α (10 ng/mL). Cells were pre-treated for 1 hour with inhibitors
prior to stimulations as described, with inhibitors purchased in-house from MRC PPU
Reagents and Services (https://mrcppureagents.dundee.ac.uk/, last accessed on 5 August
2021) and included the ERK inhibitor PD184352 (10 µM), p38 inhibitor VX-745 (1 µM),
MSK1/2 inhibitor SB747581A (10 µM), and MK2 in-hibitor PF36444022 (10 µM).
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2.14. Western Blotting
After stimulations, cells were lysed (50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM
EDTA, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 1 mM sodium pyro-phosphate,
10 mM sodium glycerophosphate, 0.27 M sucrose, 1% (vol/vol) Triton X-100 with Leupeptin
5 mg/mL, Aprotinin 5 mg/mL, PMSF 200 mM, 0.1% β-mercapto-ethanol and bromophenol
blue), boiled for 10 min, and passed through a 25nG syringe needle. Thirty µg of lysate
were separated on SDS/PAGE with a 10% polyacrylamide gel. Gels were transferred onto
nitrocellulose membrane (Amersham, GE-Health Care Life Sciences, Illinois, United States)
and blocked in 5% milk-TBS-T (50 mM Tris pH7.5, 150 mM NaCl, 0.1% (v/v) tween-20) for
1 hour. Subsequently, membranes were probed with primary antibodies overnight (18 h) at
4 ◦C using a 1 in 1000 dilution in 5% milk-TBS-T. The antibodies used were phospho-CREB
at Ser133, phospho-p38 at Thr180/Tyr182, p38-MAPK, phospho-p44/42 MAPK (Erk1/2) at
Thr202/Tyr204, p44/42 MAPK (Erk1/2), phospho-MAPKAPK-2 at Thr344, MAPKAPK-2,
phospho-HSP27 at Ser 83 (all from Cell Signalling Technologies, Danvers, United States)
(Supplementary Table S3). In-house anti-sheep MSK1 was used at 5 µg/mL, acquired from
the MRC PPU Reagents and Services (https://mrcppureagents.dundee.ac.uk/, last ac-
cessed on 5 August 2021). Membranes were probed with appropriate secondary antibodies
used at 1 in 10,000 in 5% milk-TBS-T (anti-sheep or anti-rabbit, ThermoFischer) for 1 hour
at room temperature, washed and detection was with Clarity ECL reagents from BioRad
(Hercules, CA, USA) and imaged on a Licor Odyssey Fc system.
2.15. Statistical Analysis
Statistical analysis was performed on SPSS (Chicago, IL, United States) statistical
package (v22/24/26). Data are expressed as group means ±SE.
Quantitative variables were tested for normality in GraphPad Prism (v9) (San Diego,
CA, USA) using, Anderson-Darling test, Shapiro-Wilk test, and the D’Agostino and Pearson
test. Normally distributed data containing two group comparisons were compared using
two tailed unpaired or paired students T-tests. Two or more group comparisons were
made by one- or two-way ANOVA with post-hoc Bonferroni correction. Associations
were assessed by Pearson’s correlation. Multiple linear regression was performed with
dependent variables (age, sex, BMI, systolic blood pressure, and diastolic blood pressure).
The null hypothesis was rejected at p < 0.05.
2.16. Study Approval
Patients provided written, informed consent for investigations, which conformed
to the principles outlined in the Declaration of Helsinki and local ethical approval was
granted by review boards at the University of Dundee.
3. Results
3.1. MSK1/2 Gene Expression in ST-Elevation Myocardial Infarction (STEMI) Patients
MSK1 and MSK2 gene expression was significantly lower in PBMCs from STEMI
patients when compared to healthy volunteer (HV) controls (STEMI MSK1 (p < 0.0001) and
MSK2 (p < 0.001) vs. HV) (Figure 1A,B, respectively).
We have previously reported elevated expression of inflammatory cytokines and
microvascular dysfunction in patients suffering from rheumatoid arthritis [34] and in an
animal model of systemic lupus erythematosus [32], supporting a role for systemic inflam-
mation and innate immune signalling in endothelial-dependent vascular impairment.
We assessed endothelial function by measuring FMD in our STEMI patients and found
they had significantly lower vascular responses compared with HV controls (3.7 ± 1.3% vs.
6.8 ± 1.9%, p < 0.0001) (Figure 1C). Additionally, the endothelium-independent response
to GTN was significantly lower in STEMI patients compared with HV (STEMI 8.2 ± 0.7%
vs. HV 17.8 ± 1.3%, p < 0.001). The percentage change in velocity time integral (AUC), as
an indicator of microvascular function, before and after occlusion was significantly lower
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in STEMI patients compared with HV controls (STEMI 415 ± 39% vs. HV 540 ± 39%,
p < 0.05).




Figure 1. MSK1/2 expression and endothelial function are attenuated following acute myocardial infarction. Relative 
MSK1 (A) and MSK2 (B) gene expression in peripheral blood mononuclear cells from healthy volunteers and patients 
presenting with ST-segment elevation acute myocardial infarction (STEMI). (C) Flow mediated dilation (FMD) (% cuff 
change) in STEMI patients and healthy volunteers. Pearson’s Correlation between FMD response and MSK1 (D)/ MSK2 
(E) gene expression. Healthy volunteers n = 28 STEMI n = 34. Values are group mean ± SE. A − C Unpaired T-tests. *** p < 
0.001, **** p < 0.0001. E/F Person’s correlation, dotted line represents 95% confidence interval. 
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Figure 1. MSK1/2 expression and endothelial function are attenuated following acute myocardial
infarction. Relative MSK1 (A) and MSK2 (B) gene expression in peripheral blood mononuclear
cells from healthy volunteers and patients presenting with ST-segment elevation acute myocardial
infarction (STEMI). C Flow mediated dilation (FMD) (% cuff cha ge) in STEMI patients and healthy
volunteers. Pearson’s Corr lation between FMD response and MSK1 (D)/ MSK2 (E) gen expression.
Healthy volunteers n = 28 STEMI n = 34. Values are group mean ± SE. (A–C) Unpaired T-tests.
*** p < 0.001, **** p < 0.0001. E/F Person’s correlation, dotted line represents 95% confidence interval.
In a linear regression model including age, sex, body mass index (BMI), systolic and
diastolic blood pressure, FMD was found to be independent to MSK1 gene expression
(β = 0.436, p < 0.05) (Figure 1D), MSK 2 gene expression (β = 0.340, p < 0.01) (Figure 1E) and
BMI (β = −0.280, p < 0.05). Additionally, the GTN response was found to be independent to
MSK2 gene expression (β = 0.377, p < 0.05) and BMI (β = −0.315, p < 0.05). The perce tage
change in velocity time integral (microvascular functio ) was indep ndent of MSK1 gene
expression (β = 0.341, p < 0.05) and MSK2 gene expression (β = 0.354, p < 0.01), suggesting
a role for MSK1/2 in endothelium-dependent microvascula function.
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3.2. MSK1 Kinase in Endothelial Cells
To further validate these observations, we studied MSK1 activation in dermal skin mi-
crovascular endothelial cells. We stimulated endothelial cells in vitro with pro-inflammatory
factors: lipopolysaccharide (LPS), phorbol 12-myristate 13-acetate (PMA), recombinant
mouse IL-1α, TNF-α, or p38 MAPK activator anisomycin. MSK1 was detected in skin
microvascular dermal endothelial cells (Supplementary Figures S1–S3). Anisomycin, PMA,
and TNF-α activated p38 MAPK and phosphorylated CREB (Supplementary Figures S1–S3)
and we hypothesized that MSK1/2 kinases may be involved in the development of
endothelial dysfunction.
3.3. MSK1/2 KO Mice Show Altered Plasma Cytokines but Similar Vascular Responses to WT
Mice at Study Baseline
To determine the role of MSK1/2 in vascular function, we utilized MSK1/2 KO mice
and in vivo LDI. This translational approach allowed vascular function testing longitu-
dinally in the same animal population. Baseline body weights at 16 weeks of age were
significantly greater in WT than in MSK1/2 KO mice (28 ± 1 g vs. 26 ± 1 g, respectively,
p < 0.01) (Supplementary Figure S4A). Additionally, they displayed elevations in plasma
IL-1α (p < 0.01), IL-6 (p < 0.001), soluble E-selectin (p < 0.01), and lower levels of IL-10
(p < 0.0001), when compared against WT mice (Figure 2A–D). Plasma levels of TNF-α
and total plasma cholesterol levels were similar between MSK1/2 KO and WT control
animals (Figure 2E–F). MSK1/2 KO mice had similar vascular responses to WT littermates
(Figure 3A), suggesting that the degree of systemic inflammation and potential duration
did not alter vascular function. Endothelium-dependent vascular responses are mediated
by the bioavailability of nitric oxide (NO); therefore, we studied whether MSK1/2 KO mice
exhibited changes in NO bioavailability.
3.4. L-NAME Inhibits Endothelium Dependent Vasodilation in MSK1/2 KO Mice at Baseline
At baseline, administration of the endothelial NO synthase (NOS) inhibitor, L-NAME
produced a significant reduction in the peak endothelial dependent vascular response
in MSK1/2 KO and WT control mice (320 ± 56 to 257 ± 60 AU, p < 0.01 in WT mice
and 318 ± 60 to 243 ± 65 AU, p < 0.01 in MSK1/2 KO mice). This demonstrated that
endothelium-dependent vascular responses were mediated by NO in MSK1/2 KO and WT
mice at baseline.
3.5. MSK1/2 KO Animals Show Endothelial Dysfunction and Loss of Nitric Oxide
WT mice on a standard chow diet displayed similar microvascular responses over
the study period, (Figure 3A) demonstrating preserved NO-mediated vasodilatation. WT
animals fed a cholesterol diet show attenuated vascular responses, in agreement with our
previous studies [33]. MSK1/2 KO mice on a standard chow or cholesterol enriched diet
showed significant attenuation of endothelium-dependent responses over time (p < 0.001)
(Figure 3A). MSK1/2 KO on either diet showed no significant change to L-NAME at
study week 12 (chow-fed 226 ± 18 AU versus 251 ± 18 AU, p > 0.05 and cholesterol-fed
235 ± 19 AU versus 237 ± 38, p > 0.05), indicating that diminished NO bioavailability was
responsible for the attenuated vascular responses in MSK1/2 KO mice.
3.6. Maximum and Endothelium-Independent Responses
To better understand maximal vasodilator capacity in the skin microcirculation mea-
surements using our in vivo setup, we utilized localized skin heating to 44 ◦C. We found
similar responses amongst the groups, suggesting that cholesterol feeding in WT and
MSK1/2 deficiency in mice (cholesterol and chow groups) affects endothelial function
specifically without affecting generalized smooth muscle function (Figure 3B). Importantly,
localized skin heating of the skin microvasculature provides a drug free measurement
of vascular function in rodents in combination with LDI. We confirmed endothelium-
independent microvascular responses at study end-point by iontophoresis of SNP and
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found that responses were not significantly different amongst the study groups. This
suggests localized damage to the endothelium in MSK1/2 KO animals and WT-cholesterol
fed mice (Figure 3C).




Figure 2. Plasma cytokine and cholesterol measurements in MSK1/2 knock-out (KO) and wild-type (WT) mice. (n = 36) 
wild-type and MSK1/2 knock-out (n = 38). Plasma levels of inflammatory markers in mice (pg/mL) at study baseline: (A) 
Figure 2. Plasma cytokine and cholesterol measurements in MSK1/2 knock-out (KO) and wild-type
(WT) mice. (n = 36) wild-type and MSK1/2 knock-out (n = 38). Plasma levels of inflammatory
markers in mice (pg/mL) at study baseline: (A) IL-1α, (B) IL-6, (C) sE-Selectin, (D) IL-10, (E) TNF-α,
(F) total plasma cholesterol (mg/dL). Values are group mean ± SE. (A–F) Unpaired T-tests. ** p < 0.01,
*** p < 0.001, **** p < 0.001.
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 Figure 3. Microvascular responses in MSK1/2 knockout and wild-type mice. (A) Endothelial-
dependent microvascular responses in arbitrary units (AU) over 24 weeks and (B) localized 44 ◦C
heating (over 24 weeks) and terminal endothelial-independent (C) in wild-type (WT)-chow (n = 19),
WT-cholesterol (n = 19), MSK1/2 knock-out (KO)-chow (n = 18) and MSK1/2 KO-cholesterol (n = 18)
fed animals. Longitudinal changes were analyzed by ANOVA for repeated measures followed by
post-hoc Bonferroni correction. Values are group means ± SE. *** p < 0.001 comparing genotype
responses between WT-chow and # p < 0.05, and ### p < 0.001, comparing diet with WT-chow.
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3.7. Plasma Cytokines Are Altered in MSK1/2 KO Mice and Correlate with Vascular Function
At the end of the experiment, MSK 1/2 KO cholesterol-fed mice had significantly
greater plasma IL-1α (Figure 4A) when compared to WT-cholesterol fed mice. Soluble
E-selectin (Figure 4B), TNF-α and IL-6 were significantly greater in MSK1/2 KO chow and
cholesterol-fed and MSK1/2 KO cholesterol-fed mice at study end-point, when compared
to WT-controls (Figure 4C,D). Cholesterol feeding in MSK 1/2 KO mice diminished IL-10
when compared to WT-cholesterol fed animals at study end point (Figure 1E).
Endothelium-dependent microvascular responses and localized skin heating at study
baseline showed no significant correlations with the blood derived parameters including
cytokines and cholesterol. In contrast, a number of significant correlations were observed
between blood markers and endothelium-dependent microvascular responses at study
end point. Importantly, these correlations were not present with SNP iontophoresis or
with the response to localized skin heating. Peak endothelium-dependent responses at
study endpoint (24 weeks) significantly correlated with IL-1α (R2 = −0.514, p < 0.001), IL-6
(R2 = −0.581, p < 0.001), IL-10 (R2 = 0.651, p < 0.001), TNF-α (R2 = −0.617, p < 0.001), and
E-selectin (R2 = −0.424, p < 0.001). From the univariate correlations above, these were
entered into a stepwise linear regression model. Independent determinants of endothelium-
dependent responses were IL-10 (β= 0.483, p < 0.001) and IL-1α (β= −0.286, p < 0.001).
3.8. MSK1/2 KO-Cholesterol Fed Mice Are More Susceptible to Dyslipidaemia
MSK1/2 KO-cholesterol fed mice had significant greater dyslipidaemia, when com-
pared to WT-cholesterol fed mice (Figure 4F).
3.9. Body Weights
WT-chow (baseline 27 ± 1 g vs. week 24 32 ± 1 g, p < 0.001), WT-cholesterol (baseline
30 ± 1 g vs. week 24 36 ± 1 g, p < 0.001), KO-chow (baseline 27 ± 1 g vs. week 24 32 ± 1 g,
p < 0.001) and KO-cholesterol (baseline 26 ± 1 g vs. week 24 35 ± 1 g, p < 0.001) fed mice
significantly increased in body weight over the study duration. End-point body weights
were significantly greater in cholesterol fed WT and MSK 1/ 2 KO mice (p < 0.001) when
compared to control chow fed mice (Supplementary Figure S4B).
3.10. Preservation of Endothelium-Dependent Responses and Nitric Oxide Activity in MYD88
KO-Cholesterol Fed Mice
We have previously demonstrated that MSK1/2 are activated after TLR stimula-
tion [19]. TLR activation involves the recruitment of MyD88 to initiate cytoplasmic sig-
nalling. MyD88 KO mice has been previously shown to reduce atherosclerotic plaque
formation [35,36]. However, the role of MyD88 in endothelial function has not previously
been reported in vivo. To ascertain whether TLR activation induces endothelial dysfunction
in response to dietary cholesterol, we fed MyD88 KO mice a cholesterol rich diet. MyD88
KO (27 ± 1 g) mice were significantly heavier than WT (25 ± 1 g) animals at study baseline
(p < 0.01) (Supplementary Figure S5A). MyD88 KO-cholesterol fed mice were resistant
to endothelial dysfunction in vivo (Figure 5A,B). MyD88 KO-cholesterol fed mice had
significantly lower plasma levels of IL-6 and IL-1α when compared with WT-cholesterol
control mice (Figure 5C,D). In agreement with previous reports, [35] we show that MyD88-
cholesterol fed animals display exaggerated dyslipidaemia versus WT-cholesterol fed mice
(Figure 5F,G). This supports the view that cholesterol feeding in mice induces microvascular
dysfunction and systemic cytokine expression through a TLRs-MyD88-MSK1/2 signaling
pathway. Animals in all groups significantly increased in body weight over the study
duration: WT-chow (baseline 26 ± 1 g vs. week 20 29 ± 1 g, p < 0.001), WT-cholesterol
(baseline 25 ± 1 g vs. week 20 30 ± 1 g, p < 0.001) KO-chow (baseline 27 ± 1 g vs. week 20
32 ± 1 g, p < 0.05) and KO-cholesterol (baseline 26 ± 1 g vs. week 20 30 ± 1 g, p < 0.001)
but there were no differences amongst the groups for body weights at study end point
(p > 0.05) (Supplementary Figure S5B).




Figure 4. Plasma cytokine and cholesterol measurements in MSK1/2 knockout and wild-type mice.
Wild-type (WT)-chow (n = 19), WT-cholesterol (n = 19), MSK1/2 knock-out (KO)-chow (n = 18) and
MSK1/2 KO-cholesterol (n = 18) fed mice (pg/mL). (A) IL-1α, (B) sE-Selectin, (C) TNF-α, (D) IL-6,
(E) IL-10, (F) total plasma cholesterol (mg/dL). Differences between genotype groups were tested
using two way-ANOVA followed with post-hoc Bonferroni correction. Values are group means ± SE.
** p < 0.01, *** p < 0.001, **** p < 0.0001.
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 Figure 5. Microvascular responses in MyD88 knockout and wild-type mice. (A) Endothelium-
dependent microvascular responses in arbitrary units (AU) over 20 weeks and (B) terminal
endothelium-independent in wild-type (WT)-chow (n = 9), WT-cholesterol (n = 15), MyD88 knock-out
(KO)-chow (n = 9) and MyD88 KO-cholesterol (n = 8) fed animals. Longitudinal changes were anal-
ysed by ANOVA for repeated measures followed by post-hoc Bonferroni correction. (A,B) * p < 0.05,
*** p < 0.001 comparing genotypes, # p < 0.05, ## p < 0.01 comparing diet. Plasma cytokines (pg/mL)
(C) IL-1α, (D) IL-6 and (E) IL-10 WT-chow (n = 10), WT-cholesterol (n = 10), MyD88 KO-chow
(n = 10) and MyD88 KO-cholesterol fed (n = 10) mice. Plasma measurements of (F) low density
lipoproteins and very low density lipoproteins (LDL/vLDL) and (G) high density lipoproteins (HDL)
in the plasma of WT-chow (n = 10), WT-cholesterol (n = 11), MyD88 KO-chow (n = 8) and MyD88
KO-cholesterol fed mice (n = 8) (mg/dL). (C–E) two-way ANOVA. Values are group means ± SE.
* p < 0.05, ** p < 0.01, **** p < 0.0001.
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3.11. The Role of MAPKAP 2/3 in Vascular Dysfunction and Plasma Cytokine Expression
As p38α activates MAPKAPK2 and 3 in addition to MSK1/2. We investigated the role
of MAPKAPK2 and 3 using MAPKAPK2/3 KO mice. These two kinases are important
messengers in the inflammation cascade, and their involvement is mainly in the regulation
of gene expression [21,37]. MAPKAP 2/3 have shown potential as a therapeutic target in
a KO mouse models, through abrogated cytokine release and less atherosclerotic plaque
formation in a collagen induced rheumatoid arthritis animal model [22,23].
We assessed whether MAPKAP 2/3 KO mice were susceptible to endothelial dysfunc-
tion using our in vivo model. There were no significant differences for vascular function
at study baseline between WT and MAPKAP 2/3 KO mice for endothelium-dependent
vasodilatation (Figure 6A) or maximal vasodilator dilator capacity to localized skin heating.
WT (27 ± 1 g) animals were significantly heavier than KO mice at study baseline (23 ± 1 g)
(12 weeks of age) (p < 0.001).
3.12. Preservation of Nitric Oxide in MAPKAP 2/3 KO Mice in Response to Dietary Cholesterol
MAPKAP 2/3 KO-cholesterol fed mice had similar endothelium-dependent responses
to WT-chow fed mice at study weeks 8 and 12, suggesting that MAPAKP 2/3 signalling
is involved in dietary cholesterol mediated vascular dysfunction. MAPAKP 2/3 KO-
cholesterol fed animals had greater endothelium-dependent vasodilation at study week 20
measurements when compared with WT-cholesterol fed mice. However, these observations
did not meet statistical significance for multiple comparisons (p > 0.05) (Figure 6A).
L-NAME administration to MAPKAP 2/3 KO-cholesterol fed mice at 20 weeks in-
duced significant attenuation in the peak endothelium-dependent response compared
with the response without L-NAME (p < 0.001), demonstrating preservation of NO bio-
availability. These data show that TLR-MyD88-MSK1/2 activation diminishes NO bioavail-
ability and mediates endothelial dysfunction.
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 Figure 6. Microvascular responses in MAPKAP2/3 knockout and wild-type mice. (A) Endothelium-
dependent micro-vascular responses in arbitrary units (AU) over 20 weeks and (B) terminal
endothelium-independent in wild-type (WT)-chow (n = 17), WT-cholesterol (n = 12), MAPKAP
knock-out (KO)-chow (n = 11) and MAPKAP KO-cholesterol (n = 13) fed animals. Longitudinal
changes were analysed by ANOVA for repeated measures followed by post-hoc Bonferroni correction.
(A,B) *** p < 0.001 comparing genotypes, # p < 0.05, ## p < 0.01 comparing diet. Plasma cytokines
(pg/mL) (C) IL-1α, (D) IL-6, and (E) IL-10 in WT-chow (n = 10), WT-cholesterol. (n = 10), MAPKAP
KO-chow (n = 10) and MAPKAPKO-cholesterol fed (n = 10) mice. Plasma measurements of (F) low
density lipoproteins and very low-density lipoproteins (LDL/vLDL) and (G) high density lipopro-
teins (HDL) in the plasma of WT-chow (n = 10), WT-cholesterol (n = 9), MAPKAP KO-chow (n = 9)
and MAPKAP KO-cholesterol fed mice (n = 10) (mg/dL). (C–G) two-way ANOVA values are group
means ± SE. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
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4. Discussion
In this study, we show decreased gene expression of MSK1 and MSK 2 in PBMCs
from patients presenting with STEMI. This finding correlates with attenuated endothelium-
dependent macrovascular (FMD) and microvascular (velocity time integral) function. In
mice, MSK1/2 deficiency caused elevated systemic pro-inflammatory cytokine expression
and decreased anti-inflammatory cytokine expression with significant impairment in
endothelium-dependent vasodilatation. Blood cytokine levels correlated negatively with
microvascular function in mice. Endothelium-dependent skin microvascular responses
are dependent on the bioavailability of NO. Our studies using L-NAME showed that
endothelium-dependent responses were, in part, mediated via the actions of NO, and
therefore, a reduction in endothelium-dependent responses in MSK1/2 deficient mice was
possibly mediated via loss of NO bioavailability. In contrast, WT animals fed a normal chow
diet over the 24-week study period maintained normal plasma lipids, showed no significant
changes in basal levels of inflammatory markers and had preservation of endothelium-
dependent vascular responses. Generalized vascular function, tested by iontophoresis
of the endothelium-independent vasodilator SNP and maximum vasodilator capacity to
localized skin heating was not significantly different amongst the groups, suggesting that
early elevation in pro-inflammatory cytokines was affecting vascular function specifically
at the level of the endothelium. These data suggest a possible functional role for MSK1/2
in the development and progression of CVD through an interaction between regulation of
inflammatory cytokines and endothelial dysfunction. These data support clinical studies,
which have linked blood cytokine levels to the development and progression of CVD [5–7].
Endothelial cells are not traditionally characterized as components of the innate
immune system but they express TLRs, similar to monocytes [9], macrophages [35,38] and
neutrophils [39], which are implicated in the development, progression, and regression of
vascular disease. Endothelial cells interface with circulating blood and thus alterations in
systemic cytokine expression and/or changes in plasma lipids can influence endothelial
cell biology. TLRs activation is important in the initiation of pro-inflammatory responses
in immune cells and TLR deficiency attenuates the progression of atherosclerotic plaques
in hyperlipidemic mice [35]. TLR activation can be initiated by stimuli, which are risk
factors for CVD, including oxidized low-density lipoproteins. TLR signalling is complex
and involves the recruitment of MyD88, which enables transcytoplasmic signalling and
activation of inflammatory cascades via MAPKs, p38, and NF-kB. We demonstrate here
that MyD88 is necessary for endothelial cell dysfunction in the face of hypercholesterolemia
in vivo. Similarly, TLR-MyD88 effects have been reported in a model of atherosclerosis [35],
obesity [36] and diabetes [40]. We believe this is the first description of TLR-MyD88-MSK1/
2 kinases in the initiation of early vascular disease in an in vivo rodent model relevant to
human microvascular impairment in CVD.
Baseline endothelial-dependent responses were dependent on NO in both WT and
MSK1/2 KO mice as shown by the significant reduction following pre-treatment with
L-NAME. At study baseline, although we found elevations in pro-inflammatory markers in
MSK1/2 KO mice compared with WT mice (increased IL-1α, IL-6, E-selectin and reduced
IL-10), we did not see any significant differences in endothelial-dependent responses,
perhaps indicating that the relative difference and potential duration of change in cytokine
levels was not sufficient enough to impact significantly on vascular function at that time
point. The difference in inflammatory cytokines between WT and KO mice at baseline may
be mediated by environmental factors e.g., exposure to infectious agents.
Mice were initially bred and maintained in a barrier facility and subsequently re-
housed for vascular testing in a conventional unit, at which they could have been exposed
to additional micro-organisms. The onset of CVD and induction of pro-inflammatory
gene expression in immune compromised animals has previously been reported in non-
pathogen free conditions when animals are challenged with high cholesterol feeding [41].
Previous findings show that high cholesterol feeding induces greater adverse changes in
pro-inflammatory cytokines [33], with resultant endothelial dysfunction in WT mice [42].
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Interestingly, we found that MSK1/2 KO mice fed a normal chow diet over 24 weeks
also displayed elevations in pro-inflammatory cytokines and diminished endothelial-
dependent responses. This shows that in the absence of a major CVD risk factor, i.e.,
elevated plasma cholesterol, mice lacking MSK1/2 still develop significant endothelial
dysfunction, to a degree similar to that seen with cholesterol feeding. The exact mechanism
for this dysfunction requires further scrutiny. Interestingly, despite a greater reduction
in NO bioavailability in MSK1/2 KO mice, endothelium-dependent responses in the
presence of L-NAME were not as low as responses in WT cholesterol-fed mice post L-
NAME. It is possible that the higher level of perfusion in the MSK1/2 KO mice might be
related to a compensatory increase in ACh-induced production of endothelium-derived
hyperpolarizing factor [43].
We found significant correlations between microvascular responses and levels of
cytokines at 24 weeks, which demonstrates that our methodology for assessment of mi-
crovascular function in the skin is sensitive and reflective of systemic inflammation and
is similar to what we have reported in patients [34]. IL-10 proved to be the strongest
independent determinant of endothelium-dependent response in a multivariate regression
model with IL-1α, also proving to be an independent determinant. IL-1α is unregulated in
cholesterol fed mice and can stimulate atherosclerosis [33,44]. IL-1α is synthesized by acti-
vated endothelial cells and is released early in the atherosclerotic process and mediates the
expression of cell adhesion molecules responsible for the capture, rolling, and subsequent
transmigration of immune cells into the sub-endothelial space [45]. IL-1α levels are upregu-
lated in cholesterol fed animals. These regulatory roles of IL-1 are associated with a number
of physiological events including macrophage activation, endothelial proliferation [46],
myocardial cell damage, and endothelial dysfunction through increased oxidative stress
and inflammation [47,48]. IL-6 has been linked to an increased risk of adverse cardiovascu-
lar events [49,50] and can be synthesized by a number of cells including macrophages. IL-6
inhibits endothelial NOS (eNOS) activation and attenuates vasodilation by increasing the
half-life of caveolin-1, resulting in more eNOS binding, leading to reduced bioavailability
of NO [51]. Thus, the pre-disposition of MSK1/ 2 KO mice to produce increased levels
of IL-6 may directly mediate the observed endothelial dysfunction through altered eNOS
signaling. IL-10 has a potential protective role in atherosclerosis and can be produced by
macrophages and inhibits pro-inflammatory cytokine expression through a JAK/STAT3
dependent pathway [52]. Ananieva et. al. [19] reported that the increased production of
IL-6, and to a lesser extent TNF, was dependent on the ability of MSKs to regulate IL-10
production. IL-10 KO mouse aortas display significantly blunted endothelium-dependent
responses by a reduction in eNOS expression [53]. Exogenous IL-10 treatment prevents
intimal hyperplasia in response to carotid injury in otherwise healthy mice [54]. IL-10
is anti-atherogenic and enhances uptake and efflux of cholesterol, lowering levels of cell
death and the progression of atherosclerotic lesions [55].
Taken together, the increased levels of IL-1α, IL-6, and TNF-α in MSK1/2 KO mice
could explain the observed endothelial-dysfunction in this study, although the mechanisms
of diminished NO bioavailability may be multi-modal and requires further scrutiny. It has
previously been reported that MSK1/2 KO mice have decreased production of IL-1RA [17].
IL-1RA KO mice display a significant elevation in plasma cholesterol due to impaired
cholesterol efflux through altered conversion of hepatic cholesterol to bile acids. This is
mediated by the reduced expression of 7α-hydroxylase (CY7A1), the rate limiting step
in bile acid synthesis [56]. MSK1/ 2 KO mice require further study to assess the exact
mechanism of altered cholesterol homeostasis.
5. Limitations
Our STEMI patients were recruited to the study varying in 12–100 h post PCI and
there was a bias towards male patients. Here, we describe the expressions of MSK 1/2
PBMCs in STEMI patient and show lower expression and a causal relationship between
attenuated endothelial function in patients following AMI. However, PBMCs are highly
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heterogenous and MSK 1/2 expression may vary considerably between peripheral blood
immune cell populations, such as neutrophils, monocytes, and lymphocytes, which show
distinct activation patterns following AMI. Our PBMCs samples from STEMI patients
showed invariant expression for actin-beta under our experimental conditions. However,
actin-beta expression may vary amongst individual PBMCs populations and therefore a
larger panel of housekeeper genes may be necessary in future studies looking to explore the
relationship between MSK 1/2 expression in distinct immune cell populations. Our study
focused on the role of MSK 1/2, which are activated downstream of the ERK1/2 and p38
pathways; a parallel pathway is NF-kB, which has shown roles in endothelial cell activation
and immune cell activation. It was not be possible to address all the possible pathways
activated by MyD88 using the genetic approaches we have used in this study but future
studies looking at NF-kB may benefit from the translational microvascular techniques we
have employed here. Global transgenic KO mouse models were used in these studies
and do not allow us to ascertain which individual cell types may be responsible for the
observed endothelial-dependent vascular dysfunction in the MSK 1/2 KO mouse model.
Targeted deletion using tissue specific models for endothelial and immune cell loss of MSK
1/2 will provide detailed information on how endothelial-dependent vascular dysfunction
is mediated in the absence of MSK 1/2.
6. Conclusions
In conclusion, we have shown that lack of MSK1/2 might be contributing to the in-
flammatory response following STEMI, and we have used an in vivo model to examine the
longitudinal changes in the skin microcirculation of WT and KO mice prone to inflamma-
tion. MSK1/2 plays an important role in limiting pro-inflammatory signalling downstream
of TLRs, and here we show that deletion of MSK1/2 produces a marked inflammatory
state with consequent early endothelial dysfunction and reduced NO bioavailability. Tar-
geting the MSK1/2 pathway with agents that activate MSK1 and MSK 2 might provide a
useful therapeutic option for combating inflammation-induced endothelial dysfunction,
measured by attenuated vasodilatation in the current studies.
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Abbreviations
AMI Acute myocardial infarction
AU Arbitrary unit
AUC Area under Curve




EGTA Ethylene glycol tetraacetic acid
FBS Fetal bovine serum






LDL Low density lipoprotein
LPS Lipopolysaccharide
LV Left ventricle
MAPK Mitogen activate protein kinase
MAPKAPK Mitogen activate protein kinase-activated kinase
MSK Mitogen and stress kinase
MSRU Medical school resource unit
NO Nitric oxide
NOS Nitric oxide synthase
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffered saline
PCI Percutaneous coronary intervention
PCR Polymerase chain reaction
PE Phenylephrine
ROI Region of interest
RPM Rounds per minute
SD Standard deviation
SNP Sodium nitroprusside
STEMI ST-Elevation Myocardial Infarction
TLR Toll-like receptor
TNF Tumor necrosis factor
WT Wild-type
References
1. Rahman, K.; Fisher, E.A. Insights from pre-clinical and clinical studies on the role of innate inflammation in atherosclerosis
regression. Front. Cardiovasc. Med. 2018, 5, 32. [CrossRef] [PubMed]
2. Poduri, A.; Bahl, A.; Talwar, K.K.; Khullar, M. Proteomic analysis of circulating human monocytes in coronary artery disease. Mol.
Cell. Biochem. 2012, 360, 181–188. [CrossRef]
3. Steppich, B.A.; Demetz, G.; Schulz, S.; von Wedel, J.; Pogatsa-Murray, G.; Braun, S.L.; Stein, A.; Kastrati, A.; Schömig, A.; Ott,
I. Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction.
Thromb. Res. 2011, 127, 119–121. [CrossRef]
4. Davignon, J.; Ganz, P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109, III27–III32. [CrossRef]
5. Howard-Alpe, G.M.; Sear, J.W.; Foex, P. Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of
biochemical markers. BJA Br. J. Anaesth. 2006, 97, 758–769. [CrossRef] [PubMed]
6. Pan, J.P.; Liu, T.Y.; Chiang, S.C.; Lin, Y.K.; Chou, C.Y.; Chan, W.L.; Lai, S.T. The value of plasma levels of tumor necrosis
factor-alpha and interleukin-6 in predicting the severity and prognosis in patients with congestive heart failure. J. Chin. Med.
Assoc. 2004, 67, 222–228.
Int. J. Mol. Sci. 2021, 22, 8655 20 of 22
7. Ridker, P.M.; Hennekens, C.H.; Buring, J.E.; Rifai, N. C-reactive protein and other markers of inflammation in the prediction of
cardiovascular disease in women. N. Engl. J. Med. 2000, 342, 836–843. [CrossRef]
8. Tobias, P.S.; Curtiss, L.K. Toll-like receptors in atherosclerosis. Biochem. Soc. Trans. 2007, 35, 1453–1455. [CrossRef] [PubMed]
9. Ruparelia, N.; Godec, J.; Lee, R.; Chai, J.T.; Dall’Armellina, E.; McAndrew, D.; Digby, J.E.; Forfar, J.C.; Prendergast, B.D.;
Kharbanda, R.K.; et al. Acute myocardial infarction activates distinct inflammation and proliferation pathways in circulating
monocytes, prior to recruitment, and identified through conserved transcriptional responses in mice and humans. Eur. Heart J.
2015, 36, 1923–1934. [CrossRef]
10. Menghini, R.; Campia, U.; Tesauro, M.; Marino, A.; Rovella, V.; Rodia, G.; Schinzari, F.; Tolusso, B.; di Daniele, N.; Federici,
M.; et al. Toll-like receptor 4 mediates endothelial cell activation through NF-kappaB but is not associated with endothelial
dysfunction in patients with rheumatoid arthritis. PLoS ONE 2014, 9, e99053. [CrossRef]
11. Salvador, B.; Arranz, A.; Francisco, S.; Córdoba, L.; Punzón, C.; Llamas, M.Á.; Fresno, M. Modulation of endothelial function by
Toll like receptors. Pharmacol. Res. 2016, 108, 46–56. [CrossRef] [PubMed]
12. Seeger, F.H.; Sedding, D.; Langheinrich, A.C.; Haendeler, J.; Zeiher, A.M.; Dimmeler, S. Inhibition of the p38 MAP kinase in vivo
improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res. Cardiol.
2010, 105, 389–397. [CrossRef]
13. Kyoi, S.; Otani, H.; Matsuhisa, S.; Akita, Y.; Tatsumi, K.; Enoki, C.; Fujiwara, H.; Imamura, H.; Kamihata, H.; Iwasaka, T. Opposing
effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster. Cardiovasc. Res.
2006, 69, 888–898. [CrossRef]
14. O’Donoghue, M.L.; Glaser, R.; Cavender, M.A.; Aylward, P.E.; Bonaca, M.P.; Budaj, A.; Davies, R.Y.; Dellborg, M.; Fox, K.A.;
Gutierrez, J.A.; et al. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial
Infarction: A Randomized Clinical Trial. JAMA 2016, 315, 1591–1599. [CrossRef]
15. Arthur, J.S.; Ley, S.C. Mitogen-activated protein kinases in innate immunity. Nat. Rev. Immunol. 2013, 13, 679–692. [CrossRef]
16. Kim, C.; Sano, Y.; Todorova, K.; Carlson, B.A.; Arpa, L.; Celada, A.; Lawrence, T.; Otsu, K.; Brissette, J.L.; Arthur, J.S.C.; et al. The
kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene
expression. Nat. Immunol. 2008, 9, 1019–1027. [CrossRef]
17. Darragh, J.; Ananieva, O.; Courtney, A.; Elcombe, S.; Arthur, J.S. MSK1 regulates the transcription of IL-1ra in response to TLR
activation in macrophages. Biochem. J. 2010, 425, 595–602. [CrossRef]
18. Arthur, J.S. MSK activation and physiological roles. Front. Biosci. A J. Virtual Libr. 2008, 13, 5866–5879. [CrossRef] [PubMed]
19. Ananieva, O.; Darragh, J.; Johansen, C.; Carr, J.M.; McIlrath, J.; Park, J.M.; Wingate, A.; Monk, C.E.; Toth, R.; Santos, S.G.; et al. The
kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat. Immunol. 2008, 9, 1028–1036. [CrossRef]
[PubMed]
20. Wang, X.; Liu, Y. Regulation of innate immune response by MAP kinase phosphatase-1. Cell. Signal. 2007, 19, 1372–1382.
[CrossRef] [PubMed]
21. Ronkina, N.; Kotlyarov, A.; Dittrich-Breiholz, O.; Kracht, M.; Hitti, E.; Milarski, K.; Askew, R.; Marusic, S.; Lin, L.L.; Gaestel, M.;
et al. The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor
necrosis factor biosynthesis and stabilization of p38 MAPK. Mol. Cell. Biol. 2007, 27, 170–181. [CrossRef] [PubMed]
22. Hegen, M.; Gaestel, M.; Nickerson-Nutter, C.L.; Lin, L.L.; Telliez, J.B. MAPKAP kinase 2-deficient mice are resistant to collagen-
induced arthritis. J. Immunol. 2006, 177, 1913–1917. [CrossRef] [PubMed]
23. Jagavelu, K.; Tietge, U.J.; Gaestel, M.; Drexler, H.; Schieffer, B.; Bavendiek, U. Systemic deficiency of the MAP kinase-activated
protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice. Circ. Res. 2007, 101, 1104–1112. [CrossRef]
24. Uren, N.G.; Melin, J.A.; De Bruyne, B.; Wijns, W.; Baudhuin, T.; Camici, P.G. Relation between Myocardial Blood Flow and the
Severity of Coronary-Artery Stenosis. N. Engl. J. Med. 1994, 330, 1782–1788. [CrossRef]
25. Boulanger, C.M.; Scoazec, A.; Ebrahimian, T.; Henry, P.; Mathieu, E.; Tedgui, A.; Mallat, Z. Circulating Microparticles From
Patients With Myocardial Infarction Cause Endothelial Dysfunction. Circulation 2001, 104, 2649–2652. [CrossRef] [PubMed]
26. Khan, F.; Ray, S.; Craigie, A.M.; Kennedy, G.; Hill, A.; Barton, K.L.; Broughton, J.; Belch, J.J. Lowering of oxidative stress improves
endothelial function in healthy subjects with habitually low intake of fruit and vegetables: A randomized controlled trial of
antioxidant-and polyphenol-rich blackcurrant juice. Free. Radic. Biol. Med. 2014, 72, 232–237. [CrossRef]
27. Corretti, M.C.; Anderson, T.J.; Benjamin, E.J.; Celermajer, D.; Charbonneau, F.; Creager, M.A.; Deanfield, J.; Drexler, H.; Gerhard-
Herman, M.; Herrington, D.; et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation
of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. 2002, 39, 257–265.
[CrossRef]
28. George, J.; Hussain, M.; Vadiveloo, T.; Ireland, S.; Hopkinson, P.; Struthers, A.D.; Donnan, P.T.; Khan, F.; Lang, C.C. Cardiovascular
Effects of Switching From Tobacco Cigarettes to Electronic Cigarettes. J. Am. Coll. Cardiol. 2019, 74, 3112–3120. [CrossRef]
29. Padilla, J.; Johnson, B.D.; Newcomer, S.C.; Wilhite, D.P.; Mickleborough, T.D.; Fly, A.D.; Mather, K.J.; Wallace, J.P. Normalization
of flow-mediated dilation to shear stress area under the curve eliminates the impact of variable hyperemic stimulus. Cardiovasc.
Ultrasound. 2008, 6, 44. [CrossRef] [PubMed]
30. Wiggin, G.R.; Soloaga, A.; Foster, J.M.; Murray-Tait, V.; Cohen, P.; Arthur, J.S. MSK1 and MSK2 are required for the mitogen-and
stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol. Cell. Biol. 2002, 22, 2871–2881. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 8655 21 of 22
31. Adachi, O.; Kawai, T.; Takeda, K.; Matsumoto, M.; Tsutsui, H.; Sakagami, M.; Nakanishi, K.; Akira, S. Targeted disruption of the
MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity 1998, 9, 143–150. [CrossRef]
32. Akbar, N.; Nanda, S.; Belch, J.; Cohen, P.; Khan, F. An important role for A20-binding inhibitor of nuclear factor-kB-1 (ABIN1)
in inflammation-mediated endothelial dysfunction: An in vivo study in ABIN1 (D485N) mice. Arthritis. Res. Ther. 2015, 17, 22.
[CrossRef]
33. Belch, J.J.; Akbar, N.; Alapati, V.; Petrie, J.; Arthur, S.; Khan, F. Longitudinal assessment of endothelial function in the microvascu-
lature of mice in-vivo. Microvasc. Res. 2013, 85, 86–92. [CrossRef] [PubMed]
34. Galarraga, B.; Khan, F.; Kumar, P.; Pullar, T.; Belch, J.J. C-reactive protein: The underlying cause of microvascular dysfunction in
rheumatoid arthritis. Rheumatol. 2008, 47, 1780–1784. [CrossRef]
35. Björkbacka, H.; Kunjathoor, V.V.; Moore, K.J.; Koehn, S.; Ordija, C.M.; Lee, M.A.; Means, T.; Halmen, K.; Luster, A.D.; Golenbock,
D.T.; et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity
signaling pathways. Nat. Med. 2004, 10, 416–421. [CrossRef]
36. Yu, M.; Zhou, H.; Zhao, J.; Xiao, N.; Roychowdhury, S.; Schmitt, D.; Hu, B.; Ransohoff, R.M.; Harding, C.V.; Hise, A.G.; et al.
MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated
inflammatory diseases. J. Exp. Med. 2014, 211, 887–907, Erratum in: J. Exp. Med. 2014, 211, 1003. [CrossRef] [PubMed]
37. Ronkina, N.; Menon, M.B.; Schwermann, J.; Tiedje, C.; Hitti, E.; Kotlyarov, A.; Gaestel, M. MAPKAP kinases MK2 and MK3 in
inflammation: Complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin. Biochem. Pharmacol.
2010, 80, 1915–1920. [CrossRef]
38. Sun, Y.; Ishibashi, M.; Seimon, T.; Lee, M.; Sharma, S.M.; Fitzgerald, K.A.; Samokhin, A.O.; Wang, Y.; Sayers, S.; Aikawa, M. Free
cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and
induces cathepsin K. Circ. Res. 2009, 104, 455–465. [CrossRef]
39. Feng, Y.; Zhao, H.; Xu, X.; Buys, E.S.; Raher, M.J.; Bopassa, J.C.; Thibault, H.; Scherrer-Crosbie, M.; Schmidt, U.; Chao, W. Innate
immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am. J.
Physiol.Heart Circ. Physiol. 2008, 295, H1311–H1318. [CrossRef] [PubMed]
40. Hosoi, T.; Yokoyama, S.; Matsuo, S.; Akira, S.; Ozawa, K. Myeloid differentiation factor 88 (MyD88)-deficiency increases risk of
diabetes in mice. PLoS ONE 2010, 5, e12537. [CrossRef] [PubMed]
41. Mallat, Z.; Besnard, S.; Duriez, M.; Deleuze, V.; Emmanuel, F.; Bureau, M.F.; Soubrier, F.; Esposito, B.; Duez, H.; Fievet, C.; et al.
Protective role of interleukin-10 in atherosclerosis. Circ. Res. 1999, 85, e17–e24. [CrossRef] [PubMed]
42. Meyrelles, S.S.; Peotta, V.A.; Pereira, T.M.; Vasquez, E.C. Endothelial dysfunction in the apolipoprotein E-deficient mouse: Insights
into the influence of diet, gender and aging. Lipids Health Dis. 2011, 10, 211. [CrossRef] [PubMed]
43. Verma, S.; Buchanan, M.R.; Anderson, T.J. Endothelial function testing as a biomarker of vascular disease. Circulation 2003, 108,
2054–2059. [CrossRef]
44. Freigang, S.; Ampenberger, F.; Weiss, A.; Kanneganti, T.D.; Iwakura, Y.; Hersberger, M.; Kopf, M. Fatty acid-induced mitochondrial
uncoupling elicits inflammasome-independent IL-1alpha and sterile vascular inflammation in atherosclerosis. Nat. Immunol.
2013, 14, 1045–1053. [CrossRef] [PubMed]
45. Shreeniwas, R.; Koga, S.; Karakurum, M.; Pinsky, D.; Kaiser, E.; Brett, J.; Wolitzky, B.A.; Norton, C.; Plocinski, J.; Benjamin, W.;
et al. Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of
leukocyte adhesion molecules on the vessel surface. J. Clin. Invest. 1992, 90, 2333–2339. [CrossRef] [PubMed]
46. Hoge, M.; Amar, S. Role of interleukin-1 in bacterial atherogenesis. Timely Top. Med. Cardiovasc. Dis. 2007, 11, E5. [CrossRef]
[PubMed]
47. Chi, H.; Messas, E.; Levine, R.A.; Graves, D.T.; Amar, S. Interleukin-1 receptor signaling mediates atherosclerosis associated with
bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: Pharmacotherapeutic implications.
Circulation 2004, 110, 1678–1685. [CrossRef] [PubMed]
48. Chamberlain, J.; Evans, D.; King, A.; Dewberry, R.; Dower, S.; Crossman, D.; Francis, S. Interleukin-1beta and signaling of
interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am. J. Pathol. 2006, 168,
1396–1403. [CrossRef]
49. Naya, M.; Tsukamoto, T.; Morita, K.; Katoh, C.; Furumoto, T.; Fujii, S.; Tamaki, N.; Tsutsui, H. Plasma interleukin-6 and tumor
necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens. Res. 2007, 30, 541–548.
[CrossRef]
50. Ridker, P.M.; Rifai, N.; Stampfer, M.J.; Hennekens, C.H. Plasma concentration of interleukin-6 and the risk of future myocardial
infarction among apparently healthy men. Circulation 2000, 101, 1767–1772. [CrossRef]
51. Hung, M.J.; Cherng, W.J.; Hung, M.Y.; Wu, H.T.; Pang, J.H. Interleukin-6 inhibits endothelial nitric oxide synthase activation and
increases endothelial nitric oxide synthase binding to stabilized caveolin-1 in human vascular endothelial cells. J. Hypertens. 2010,
28, 940–951. [CrossRef] [PubMed]
52. Pattison, M.J.; Mackenzie, K.F.; Arthur, J.S. Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine
production by blocking IL-10-mediated feedback. J. Immunol. 2012, 189, 2784–2792. [CrossRef]
53. Zemse, S.M.; Chiao, C.W.; Hilgers, R.H.; Webb, R.C. Interleukin-10 inhibits the in vivo and in vitro adverse effects of TNF-alpha
on the endothelium of murine aorta. Am. J. Physiol. Heart Circ. Physiol. 2010, 299, H1160–H1167. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 8655 22 of 22
54. Zimmerman, M.A.; Reznikov, L.L.; Raeburn, C.D.; Selzman, C.H. Interleukin-10 attenuates the response to vascular injury. J. Surg.
Res. 2004, 121, 206–213. [CrossRef] [PubMed]
55. Han, X.; Kitamoto, S.; Wang, H.; Boisvert, W.A. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in
hyperlipidemic mice. FASEB J. 2010, 24, 2869–2880. [CrossRef] [PubMed]
56. Isoda, K.; Ohsuzu, F. The effect of interleukin-1 receptor antagonist on arteries and cholesterol metabolism. J. Atheroscler. Thromb.
2006, 13, 21–30. [CrossRef]
